Novo Nordisk

News

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.

News

Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.

Market Access

Recent advancements in weight-loss interventions are transforming the healthcare landscape and presenting new M&A opportunities

News

Novo Nordisk has moved to shore up its obesity pipeline with a $2bn licensing deal for a triple agonist developed by China's United Biotechnology.

News

Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."

News

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.